This report provides updated uniform criteria for use by public health professionals when reporting the nationally notifiable infectious diseases listed in Part One of this report. A revision date is included for case definitions that have been revised. The case definitions for some infectious conditions not designated as nationally notifiable are included in Part Two of this report.
This report summarizes potential uses of nucleic acid amplification (NAA) tests such as the Amplified Mycobacterium Tuberculosis Direct Test (MTD) for TB diagnosis and provides interim guidelines for the use of such tests. The report lists the current NAA tests, their FDA approved uses, their non-approved indications also known as off-label uses, limitations, and cautions.
This report in the form of a notice to readers states that CDC in conjunction with the American Thoracic Society expects to issue new guidelines on screening and preventive therapy for TB that will include a recommendation on the use of the two-month regimen of daily rifampin and pyrazinamide (2RZ) as an alternative to 12-month isoniazid for prevention of TB in HIV-negative persons for whom preventive therapy is indicated. A comparative trial of the 2RZ regimen in HIV-negative persons has not been conducted.
